Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer Research, of final results from the EXALT-1 trial. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential real-world impact of using Exscientia’s AI-supported precision medicine platform (referred to in the study as single-cell functional precision medicine or scFPM) to propose which therapy would be most effective for late-stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples. Interim data from the study was previously published in The Lancet Haematology.
“Precision medicine is the right drug, for the right patient, at the right time. By enabling the robust and accurate assessment of drug effect on viable patient samples at single-cell resolution, we have created a technology that can provide hemato oncologists prediction of a patient’s response prior to deciding on a course of therapy,” said Gregory Vladimer, Ph.D., VP of translational research at Exscientia and co-inventor of the platform technology. “While the use of genetics in precision cancer medicine can determine if a target is present, functionally characterizing available drug options on patient cells within a short time window provides evidence for cancer cell sensitivity.”
"The EXALT-1 study was the first-ever prospective study of its kind, demonstrating the potential of a functional precision medicine platform to identify the optimal therapy for an individual patient. The results of the trial are clear: patients who were treated using recommendations guided by single-cell drug screenings from real-time biopsies remained progression-free longer as compared to their previous line of therapy,” commented Philipp P. Staber, M.D., Ph.D., haematologist oncologist at Medical University Vienna and principal investigator of the study.
The prospective, single-arm, open label EXALT-1 study was a basket trial for patients with a variety of aggressive haematological cancers. The study evaluated a total of 76 patients. Of these, 56 patients were treated according to scFPM and 20 patients received treatment based on physician’s choice. At a median follow-up of 23.9 months, 54% of patients (30/56) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival (PFS) compared to their previous therapy, with 40% of responders (12/30) achieving exceptional responses lasting at least three times longer than expected for their respective disease. The PFS on scFPM-guided treatment was significantly increased (p=0.0093). Of note, 23% of patients (13/56) were progression-free after 12 months after scFPM-guided therapy, compared to only 5% of patients (3/56) on their previous treatment. The objective response rate was 55% for patients treated according to scFPM results.
Giulio Superti-Furga, Scientific Director of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences said, “The current study is a wonderful example of how successful collaboration with academic research and innovation, clinical expertise, and pharmatech knowhow can benefit patients and the development of new technologies. This is not personalised medicine inferred from biomarkers, it is really measured. It is based on function.”
Exscientia’s precision medicine platform uses AI techniques to conduct single-cell, high content analysis of individual patient tissue samples to generate clinically-relevant insights into which treatments will deliver the most benefit to an individual patient. The underlying technology was developed by Dr. Gregory Vladimer and Prof. Berend Snijder, now at the ETH Zurich, while working in the laboratory of Giulio Superti-Furga at the CeMM Research Center for Molecular Medicine in Austria.
“Exscientia’s patient-first AI strategy aims to bring patients directly into all aspects of new medicine discovery and development, including target discovery, drug optimization and patient selection for clinical trials,” said Andrew Hopkins, Ph.D., Founder and Chief Executive Officer of Exscientia. “These results provide strong validation for our strategy to apply AI to modernize drug development, ultimately aiming to bring better drugs, faster, to patients in need.”
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
CeMM Research Center for Molecular Medicine is an interdisciplinary research institute of the Austrian Academy of Sciences committed to advancing the understanding of human diseases through basic and biomedical research. Located in the midst of the campus of the Medical University of Vienna, CeMM is dedicated to its mission statement to pioneer science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM’s research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. The institute is committed to identifying, supporting, and developing its research discoveries into impactful solutions for society. www.cemm.at
The Medical University of Vienna is a traditional medical education establishment with nearly 7,500 students and approximately 6,000 staff members, and an important top-level biomedical research institution in Europe. Its international outlook is one of its most important pillars and the research focus is centered on immunology, cancer research, imaging, brain research and cardiovascular diseases. www.meduniwien.ac.at/web/en
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations regarding the ability of its AI-supported precision medicine platform to conduct single-cell, high content analysis of individual patient tissue samples to generate clinically-relevant insights into which treatments will deliver the most benefit to an individual patient. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the AI-supported precision medicine platform discussed above will be successful in proposing which treatment would be most effective for individual patients, including late-stage haematological cancer patients. The success of the platform to match targeted therapies to individual patients is subject to numerous factors, many of which are beyond the control of Exscientia, including, without limitation, the ability of healthcare providers to collect viable cells and each patient’s ability to respond due to pretreatments. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Medical University of Vienna:
CeMM Research Center for Molecular Medicine:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SkyHive Raises $40M Series B to Reskill Workforces and Advance the Digital Labor Economy20.10.2021 17:00:00 EEST | Press release
SkyHive (the “Company”), the SaaS platform providing workforce transformation and labor market development guidance, today announced a $40 million Series B investment round led by Eldridge, with participation from other investors Allegis Cyber, Accenture Ventures, Workday Ventures, and the Partnership Fund For New York City. Recently recognized by The World Economic Forum as a 2021 Technology Pioneer, SkyHive is solving dislocation in modern labor economics and human capital management using its proprietary Quantum Labor Analysis (QLA) methodology, which is active in 90 countries and 400,000 unique locations worldwide. QLA combines economic theory, workforce modelling, human analytics, and data science to provide real-time insights on workforces and external labor markets. The platform also identifies high-value emerging skillsets and actively helps organizations reskill their professionals. “Reskilling the world at scale and with pace is only achieved by successfully blending art and
Silicon Valley Veterans Launch pulsESG™—an Integrated SaaS Platform for Enterprise ESG Analysis with $8.5M in Seed Funding from Impact-Driven Investors20.10.2021 16:00:00 EEST | Press release
pulsESG™ today announced the launch of its enterprise environmental, social, and governance (ESG) software as a service (SaaS) platform backed by $8.5 million in seed funding from leading impact-driven investors and led by two Silicon Valley enterprise software veterans. The platform distinguishes itself in the marketplace through features such as model-driven architecture and full integration with both internal sources of data and external investor-facing systems, empowering companies to track and derive insights for ESG compliance and improvement based on stakeholder requirements. The company emerged from stealth mode today and the product is expected to be made generally available in Q1 2022. Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESG™ platform is designed to take a different approach to ESG analysis than what currently exists in the marketplace by providing comprehensive, auditable, and accurate deep analytics that can be integrated with both
Interaxon Inc. (Muse®) Launches the Latest in Non-Pharmaceutical Sleep Support: EEG-Powered ‘Digital Sleeping Pills’ That Provide Immediate & Intelligent Support for Falling Asleep & Nighttime Interruptions20.10.2021 16:00:00 EEST | Press release
Interaxon Inc. (Muse®), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/ Muse today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night. (Photo: Business Wire) Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experi
ExOne Showcases Ability to 3D Print Virtually Any Powder Material in New Corporate Video, “Let’s Make it Right”20.10.2021 15:30:00 EEST | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that it is open to developing virtually any powder material in partnership with manufacturers for their specific application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005203/en/ The ExOne Company has released a new corporate video, "Let's Make it Right," showcasing the ability of its sustainable binder jetting technology to 3D print virtually any type of powder. ExOne has already qualified more than 20 metals, ceramics and composites for 3D printing, but is now developing materials such as pulverized concrete and other waste products with customers. (Photo: Business Wire) The material flexibility and sustainability of ExOne’s patented binder jet 3D printing technology is showcased in a new corporate video unveiled today, “Let’s Make it Right.” The video is a celebration of
Workiva Announces 2021 Partner of the Year Award Winners20.10.2021 15:00:00 EEST | Press release
Workiva Inc. (NYSE:WK), the company that simplifies complex work, announced the winners of the 2021 Workiva Partner of the Year Awards. The awards recognize partners that have leveraged their significant industry and solution-specific experience to help customers expand their use of the Workiva platform to drive transparency in reporting and compliance. Award recipients were recognized during the Company’s virtual Global Partner Summit, held October 18 & 19. “Our partners are instrumental in deploying the Workiva platform as a critical component in digital transformations across global enterprises,” said Corey Wells, vice president of partnerships and alliances at Workiva. “It’s an honor to recognize this year’s winners for helping drive the innovation and collaboration that has made a lasting impact on our customers' business.” 2021 Partner of the Year Award Winners Global Partner of the Year - Deloitte Global Technology Partner of the Year - FloQast North American Advisory Partner of
BentallGreenOak Achieves New High Mark for Exceptional Performance in the 2021 Global Real Estate Sustainability Benchmark (GRESB), Marking 11 Consecutive Years of Excellence and Industry Leadership in ESG20.10.2021 15:00:00 EEST | Press release
BentallGreenOak (BGO) announced today that, in a consecutive run of industry leadership now marking 11 years, its global real estate investment platform has achieved a new high mark for exceptional performance in the annual Global Real Estate Sustainability Benchmark (GRESB). Four of BGO’s flagship investment strategies, already amongst the best performing funds in their global categories, achieved five star ratings and higher scores in 2021, reinforcing a firm-wide commitment to enhanced, year-over-year performance in ESG across its platform. For the first time in BGO’s 11 years of GRESB participation, all BGO funds participating in the Development module — which measures an entity’s efforts to address ESG issues during a building’s design, construction and renovation phases — ranked first in their peer group, achieving Sector Leader status. Highlights from BentallGreenOak’s 2021 GRESB scores: All BGO Funds scored 100% on the Management component of GRESB, demonstrating leadership in
Slate Asset Management Expands European Platform with NOK 1 Billion Essential Real Estate Portfolio Acquisition in Norway20.10.2021 14:23:00 EEST | Press release
Slate Asset Management ("Slate”), a global alternative investment platform focused on real estate, announced today the acquisition of a portfolio of 25 essential real estate assets in Norway for approximately NOK 1 billion. The acquisition – Slate’s first in the Nordics – further scales the firm’s European platform and significantly increases Slate’s exposure to high-quality essential real estate assets in broader Europe. The portfolio comprises approximately 50,000 square meters geographically dispersed across Norway, with the majority concentrated in and around Norway’s five largest cities. The entirety of the portfolio’s income is generated by essential goods and service providers, including 24 grocery stores let to class-A tenants and one government-tenanted medical facility. The portfolio’s three major operators are leading Norwegian grocery groups Coop Norge, Reitan Group and NorgesGruppen, which hold around 96% of the total grocery market share in Norway. “We are actively increa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom